CSPC Pharma Revenue, Profits - CHPTY Annual Income Statement

Add to My Stocks
$101.08 $0 (0%) CHPTY stock closing price Nov 29, 2017 (Closing)

Fundamental analysis of CHPTY stock involves analyzing its financial statements, apart from checking the CSPC Pharma stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement for CHPTY which shows a YOY revenue growth of 8.39% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. One also needs to look at CSPC Pharma assets, operating expenses and CSPC Pharma free cash flow. The CSPC Pharma profit and loss statement shows revenue of $1.59B for 2016. Revenue has grown by 8.39% YOY for CHPTY stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201620152014201320122011201020092008
CSPC Pharma Revenues or Net Sales
1.59B1.47B1.41B1.28B534.47M948.26M1B907.07M876.97M
Cost Of Goods Sold (COGS)780.55M796.29M873.03M878.58M301.76M757.88M707.95M614.59M584.04M
CSPC Pharma Gross Profit
812.57M673.49M540.16M403.85M232.7M190.37M292.61M292.48M292.92M
Research & Development Expense---------
Selling General & Admin Expense471.32M394.02M324.17M247.62M127.95M141.91M161.35M141.47M126.5M
Income Before Depreciation Depletion Amortization341.25M279.47M215.99M156.23M104.75M48.46M131.25M151M166.41M
Depreciation Depletion Amortization---------
Non Operating Income3.54M--13.93M199.56M1.35M1.12M3.24M-24.14M
Interest Expense5.37M7.26M7.01M9.35M7.74M9.42M8.2M9.01M-
CSPC Pharma Pretax Income
339.43M272.45M209.17M160.81M296.57M40.39M124.16M145.22M142.26M
Provision for Income Taxes67.24M55.78M43.49M33.29M17.01M8.21M24.44M18.41M20.67M
MinorityInterest1.59M1.85M-------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations272.18M216.67M165.67M127.52M279.56M32.18M99.71M126.81M121.59M
Extraordinary Items & Discontinued Operations---------
CSPC Pharma Profit/ Loss (Net Income)
270.58M214.82M165.67M127.52M279.56M32.18M99.71M126.81M121.59M
Average Shares used to compute Diluted EPS119.2M119.15M119.35M117.59M91.67M30.63M30.7M30.7M30.76M
Average Shares used to compute Basic EPS119.2M118.18M118.16M111.24M29.26M30.63M30.7M30.7M30.76M
Income Before Nonrecurring Items270.63M214.82M163.63M125.39M278.71M29.96M96.74M123.17M120.19M
Income from Nonrecurring Items-------2.05M-
CSPC Pharma Earnings Per Share Basic Net
2.271.821.381.139.500.983.154.083.93
CSPC Pharma Earnings Per Share Diluted Net
0.231.801.371.073.350.983.154.083.93
EPS Diluted Before Nonrecurring Items0.231.801.371.073.350.983.154.013.91
Preferred Dividends Acc Pd---------
Dividends Common---------
Dividend Per Share Common0.690.620.500.620.001.521.521.270.30
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Grifols financial analysis

It is very helpful to read a report on CSPC Pharma stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: CSPC Pharma revenue chart implies that the company is growing. It has been the case with CSPC Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. CHPTY stock had a healthy bottom line growth.

The income statement is also called the profit and loss statement. Apart from the CHPTY income statement, one can check the CSPC Pharma historical stock prices to check how the price has moved with time.

CSPC Pharma Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
39.8
PS Ratio (price sales ratio)
7.08
Net Profit Margin
18.1
Dividend Yield
0.74%

Annual Income Statements - CSPC Pharmaceutical Group Ltd (ADR) Industry Peers

Grifols income statement, Guangzhou Pharma income statement, Merck KGAA income statement, Sagent Pharma income statement